Aileron Therapeutics, Inc. Announces Resignation of Nolan Sigal, M.D., Ph.D. from Board of Directors, Member of Nominating and Corporate Governance Committee
March 01, 2024 at 04:07 pm EST
Share
On February 29, 2024, Nolan Sigal, M.D., Ph.D., notified Aileron Therapeutics, Inc. of his decision to resign as a member of the Board of Directors of the Company, effective immediately.
With his resignation, Dr. Sigal also resigned as a member of the Company?s Nominating and Corporate Governance Committee.
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
Aileron Therapeutics, Inc. Announces Resignation of Nolan Sigal, M.D., Ph.D. from Board of Directors, Member of Nominating and Corporate Governance Committee
AILERON THERAPEUTICS, INC. 
